Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy
- 22 April 2025
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 212 (1) , 79-86
Abstract
Purpose Pembrolizumab plus neoadjuvant chemotherapy (P-CT) is the new standard in early-stage triple-negative breast cancers (TNBC). Pembrolizumab impact on ovarian reserve remained unknown. We evaluated the impact of pembrolizumab on ovarian reserve, through plasmatic Anti-Müllerian (AMH) analysis, in young TNBC patients. Methods TNBC patients < 43 years treated by P-CT (carboplatin/paclitaxel/epirubicin/cyclophosphamide plus pembrolizumab) of which plasma samples were available before and after treatment were included retrospectively (P-CT group). AMH, FSH, and estradiol were analyzed before and after treatment, then compared to a retrospective cohort of TNBC patients treated with chemotherapy alone (cyclophosphamide/anthracycline/taxanes) (No-P group). Results P-CT patients (N = 17) and No-P patients (N = 62) had comparable median age, BMI, smoking exposure, BRCA status, oral hormonal contraceptive use at diagnosis, and baseline AMH. Drugs used were comparable in both groups, except for carboplatin and pembrolizumab, only used in P-CT group. One year after the start of treatment, AMH fell from 1.08 to 0.01 ng/mL (p = 0.0001) and from 1.39 to 0.018 ng/mL (p < 0.0001), in the P-CT and No-P groups, respectively, without difference according to pembrolizumab exposure (p = 0.25). 9/17 P-CT patients (53%), and 21/62 No-P patients (34%), had undetectable AMH after treatment (p = 0.25). FSH and estradiol were comparable between the two groups, before and after treatment. Conclusion No additional impact of pembrolizumab versus chemotherapy alone on AMH evolution was observed in TNBC patients < 43 years. Nevertheless, undetectable AMH 1 year after the start of treatment was common in the P-CT group. Larger studies are essential to confirm these preliminary results and assess long-term impact of pembrolizumab on ovarian reserve.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Evaluation of Female Fertility—AMH and Ovarian Reserve TestingThe Journal of Clinical Endocrinology & Metabolism, 2022
- Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patientsInternational Journal of Cancer, 2022
- Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancerBreast Cancer Research and Treatment, 2022
- Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproductionReproductive BioMedicine Online, 2022
- Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic reviewESMO Open, 2021
- Epidemiology of Triple-Negative Breast CancerThe Cancer Journal, 2021
- Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based ChemotherapyFrontiers in Oncology, 2019
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysisAnnals of Oncology, 2018
- The physiology and clinical utility of anti-Müllerian hormone in womenHuman Reproduction Update, 2014
- The Relationship Between Anti-Müllerian Hormone in Women Receiving Fertility Assessments and Age at Menopause in Subfertile Women: Evidence From Large Population StudiesThe Journal of Clinical Endocrinology & Metabolism, 2013